Background: B-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS (ocrelizumab). …
Read MoreBackground: B-cell depleting agents are FDA approved for the treatment of RRMS (ocrelizumab (OCR) and ofatumumab (OFA)) and PPMS (ocrelizumab). …
Read MoreBackground: A significant clinical need exists for a broad range of health care professionals to be able to objectively screen …
Read MoreBackground: Given the high prevalence of anxiety and depression in MS, many patients struggle to find high quality, professional mental …
Read MoreBackground: Although FDA-approved COVID vaccines prevent severe infections in the general population, their efficacy in the face of immune modulation …
Read MoreBackground: Infections in people with multiple sclerosis (PwMS) may have a detrimental effect on disease progression, risk of hospitalization, and …
Read MoreBackground: Cladribine, a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, may disrupt the central immune cascade in persons with multiple …
Read MoreBackground: US payers are looking to reduce the cost of administering infusible drugs for multiple sclerosis (MS). Home-based infusion has …
Read MoreBackground: The etiology of multiple sclerosis (MS) is not fully understood, and the disease may be triggered or exacerbated by …
Read MoreBackground: The COVID-19 epidemic raises important questions about the efficacy of vaccines for people treated with ocrelizumab (OCR), an anti-CD20 …
Read MoreBackground: Vaccinations comprise an important component of MS management. Data are needed regarding whether ofatumumab (OMB) impacts humoral immune response …
Read MoreBackground: There are two mRNA vaccines targeting the SARS-CoV2 virus widely used in the U.S. There is limited knowledge about …
Read MoreBackground: The COVID-19 pandemic ushered in a new era of telehealth to decrease transmission of the SARS-CoV-2 virus. While this …
Read MoreBackground: Research into the impact of COVID-19 on people with MS is ongoing. Objectives: To gain an understanding of COVID-19 …
Read MoreBackground: Multiple sclerosis (MS) is a chronic, disabling neurological disease that attacks young adults. Similar to many other chronic conditions …
Read MoreBackground: Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved for the treatment of relapsing multiple sclerosis (RMS) in adults. …
Read MoreBackground: Natalizumab 4-week dosing (Q4W) with 300 mg is approved for treatment of relapsing-remitting multiple sclerosis. Dosing frequency of approximately …
Read MoreBackground: Inebilizumab is a humanized, affinity-optimized, anti-CD19 monoclonal antibody approved in Japan, South Korea and the USA to treat neuromyelitis …
Read MoreBackground: Vaccines against SARS-CoV-2 are a key component of public health measures to combat the COVID-19 pandemic. The impact of …
Read MoreBackground: Certain DMTs may negatively impact the humoral response to SARS-COV-2 vaccines. However, many MS-related clinical, demographic, and immunological variables …
Read MoreBackground: Multiple sclerosis (MS) is a chronic neurological disorder and a major cause of disability in young adults. Cladribine tablets …
Read MoreBackground: Multiple sclerosis (MS) is a chronic immune-mediated neurological disease affecting mainly young adults. MS patients are more prone to …
Read More3 University Plaza Drive, Ste 116
Hackensack, NJ 07601
(201) 487-1050
info@mscare.org
© 2021 CMSC